Siemens PETNET Solutions Signs Nationwide Commercial Agreement to Manufacture and Distribute Lilly's Molecular Imaging Agent

MALVERN, Pa., and KNOXVILLE, Tenn., Nov. 7, 2011 /PRNewswire/ -- PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., has entered into a nationwide commercial agreement with Eli Lilly and Company that grants Siemens PETNET Solutions the right to manufacture and distribute Lilly's molecular imaging agent that is currently under review by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging.

(Logo:  http://photos.prnewswire.com/prnh/20070904/SIEMENSLOGO )

With the industry's largest network of PET biomarker production facilities worldwide, Siemens PETNET Solutions is the first company to sign an agreement for the commercial manufacturing and distribution of Lilly's molecular imaging agent in the U.S., should it be FDA approved.  Additionally, should Lilly's molecular imaging agent be approved in markets outside the U.S., the companies would consider expanding this commercial agreement to those markets as well.

"This commercial agreement with Lilly is another proof point that Siemens is at the forefront of providing leading diagnostic solutions that advance our mission: to provide physicians and patients with an integrated approach to diagnosing diseases," said Britta Fuenfstueck, CEO of Molecular Imaging, Siemens Healthcare. "Optimized solutions, from tracer manufacturing to innovative scanner technologies of the Biograph product family of PET/CT and PET/MR products and related processing solutions, support an efficient diagnostic process."

The Siemens Healthcare Sector (NYSE: SI) is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2010 (to September 30), the Sector posted revenue of 12.4 billion euros and profit of around 750 million euros. For further information please visit: www.siemens.com/healthcare.

SOURCE Siemens Healthcare